Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (S)-Nitrendipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F known ✓ | O60840 | 9/20 | 0.91 |
| ▸ | CACNA1D known ✓ | Q01668 | 9/20 | 0.91 |
| ▸ | CACNA1S known ✓ | Q13698 | 9/20 | 0.91 |
| ▸ | CACNA1C known ✓ | Q13936 | 9/20 | 0.91 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-Nitrendipine SCHEMBL38973 | 1.00 | HIF1A (1.00) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL29465067 | 1.00 | HIF1A (1.00) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL15516493 | 1.00 | HIF1A (1.00) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL38972 | 1.00 | HIF1A (1.00) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| (R)-Nitrendipine SCHEMBL30228952 | 1.00 | HIF1A (1.00) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL28250729 | 0.99 | HIF1A (0.98) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL27589897 | 0.99 | HIF1A (0.98) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL10914240 | 0.99 | HIF1A (0.98) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL28360428 | 0.99 | HIF1A (0.98) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL23647366 | 0.96 | HIF1A (0.92) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1967 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-20250163026-A1 | Deuterium-Enriched Nirmatrelvir as SARS-CoV-2 Mpro Inhibitor for the Treatment of COVID-19 | DHANOA DALJIT SINGH (US) | 2025-05-22 | — | — | US | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | claimed |
| US-11634428-B2 | Deuterated angiotensin-converting enzyme-2 (ACE-2) inhibitors | DHANOA DALJIT SINGH (US) | 2023-04-25 | — | — | US | claimed |
| US-20230039319-A1 | DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES | DHANOA DALJIT SINGH (US) | 2023-02-09 | — | — | US | claimed |
| US-20220306646-A1 | Deuterated Angiotensin-Converting Enzyme-2 (ACE-2) Inhibitors | DHANOA DALJIT SINGH (US) | 2022-09-29 | — | — | US | claimed |
| WO-2022160971-A1 | CONCENTRATE CONTAINING POORLY SOLUBLE DRUG, AND EMULSION PREPARED THEREFROM | 北京德立福瑞医药科技有限公司 | 2022-08-04 | — | — | WO | claimed |
| WO-2022124342-A1 | AGENT FOR CANCER THERAPY, AND SCREENING METHOD FOR ACTIVE INGREDIENT THEREOF | 国立大学法人 岡山大学 | 2022-06-16 | — | — | WO | claimed |
| WO-2021118826-A1 | DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES | DHANOA DALJIT (US) | 2021-06-17 | — | — | WO | claimed |
| WO-2000018402-A1 | METHOD FOR TREATING ANDROGEN-RELATED CONDITIONS | MERCK & CO., INC. (US) | 2000-04-06 | — | — | WO | claimed |
| WO-1999067231-A1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX S.A. (FR) | 1999-12-29 | — | — | WO | claimed |
| WO-1999044579-A2 | USE OF A COMPOUND INHIBITING THE ACTIVITY OF A SODIUM CHANNEL AND A CALCIUM CHANNEL IN A COMPOSITION FOR TOPICAL USE | L'OREAL (FR) | 1999-09-10 | — | — | WO | claimed |
| WO-1999025347-A2 | CHEMICAL COMPOUNDS HAVING ION CHANNEL BLOCKING ACTIVITY FOR THE TREATMENT OF IMMUNE DYSFUNCTION | NEUROSEARCH A/S (DK) | 1999-05-27 | — | — | WO | claimed |
| WO-1999008676-A1 | COMPOSITIONS CONTAINING BERGAMOTTIN FOR INCREASING THE ORAL BIOAVAILABILITY OF PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-02-25 | — | — | WO | claimed |
| EP-0489108-B1 | Use of spiperone derivatives for immunosuppression | BETH ISRAEL HOSPITAL (US) | 1996-03-13 | — | — | EP | claimed |
| EP-0319983-B1 | ASSOCIATION OF PYRIMIDINE DERIVATIVES AND CALCIUM ANTAGONISTS TO INDUCE AND STIMULATE THE HAIR GROWTH AND TO REDUCE HAIR LOSS | L'OREAL (FR) | 1992-06-03 | — | — | EP | claimed |
| EP-0224810-B1 | ANTIHYPERTENSIVE PREPARATION CONTAINING A MIXTURE | BAYER AG (DE) | 1989-07-19 | — | — | EP | claimed |
| EP-0319983-A1 | Association of pyrimidine derivatives and calcium antagonists to induce and stimulate the hair growth and to reduce hair loss | L'OREAL (FR) | 1989-06-14 | — | — | EP | claimed |
| CN-85102334-A | The method for preparing dihydropyridine preparation | — | 1987-01-24 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634428-B2 | Deuterated angiotensin-converting enzyme-2 (ACE-2) inhibitors | ACE2, ACE, REN | CACNA1F 3568/4885CACNA1D 3302/4885CACNA1S 3189/4885 |
| US-20230039319-A1 | DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES | AGTR2, AGTR1, EDNRA | CACNA1F 2023/4885CACNA1D 1831/4885CACNA1S 1765/4885 |
| US-20250163026-A1 | Deuterium-Enriched Nirmatrelvir as SARS-CoV-2 Mpro Inhibitor for the Treatment of COVID-19 | TMPRSS2, ACE2, TMPRSS4 | CACNA1F 4313/4885CACNA1D 4126/4885CACNA1S 4103/4885 |
| US-20220306646-A1 | Deuterated Angiotensin-Converting Enzyme-2 (ACE-2) Inhibitors | ACE2, ACE, REN | CACNA1F 3568/4885CACNA1D 3302/4885CACNA1S 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.